Evenity denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for evenity are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Limits Evenity Quantities — and Why You Can Appeal

Evenity (romosozumab) is a bone-building injectable approved for postmenopausal osteoporosis at high fracture risk. Aetna's quantity-limit restrictions typically mirror the FDA-approved treatment duration stated in the prescribing label, which specifies a defined course of therapy rather than indefinite use. Denials citing quantity limits most often occur when the requested supply exceeds that authorized duration or when the plan's internal policy imposes an additional dispensing cap. These restrictions are reviewable and frequently overturned when the prescriber's documentation clearly maps the request to the approved label.

## The Federal Appeal Framework

Under ACA §2719, non-grandfathered commercial plans must offer internal appeal followed by an independent external review. You generally have up to 180 days from the denial notice to file an internal appeal and, after exhausting internal options, four months to request external review through a state-certified or federal independent review organization (IRO). If your condition could deteriorate while waiting, request an expedited appeal, which compresses the review timeline to 72 hours for urgent cases.

If your coverage is employer-sponsored and self-funded, ERISA §503 governs; you are entitled to a full-and-fair review with written explanation of any adverse benefit determination, and federal-court review is available after exhausting plan remedies.

## Documentation to Gather

• Diagnosis confirmation: DXA bone-density report with T-score, fracture history (imaging, operative/discharge records), and treating physician's diagnosis code linking to high-risk osteoporosis.
• Prior treatment history: Dated records showing which bone-loss therapies were tried previously, duration of each, and clinical response or reason for discontinuation.
• Clinical severity: Chart notes quantifying fracture risk and any comorbidities that elevate urgency.
• Prescriber's medical-necessity letter: A letter from the ordering clinician explaining why the requested quantity aligns with the FDA-approved prescribing label and why the course of therapy cannot be abbreviated without clinical harm.
• The FDA prescribing label itself: Print and attach the relevant section from the current FDA-approved label specifying the authorized treatment duration.

## Criteria-Mapping Structure

Build a side-by-side table in your appeal packet:

| Aetna Policy Requirement | Chart Evidence Meeting It | |---|---| | [Copy each quantity-limit criterion directly from Aetna's published medical/coverage policy] | [Insert the exact chart fact, date, and document source that satisfies it] |

Obtain Aetna's current clinical policy for Evenity directly from Aetna's provider policy library or request it in writing as part of the denial process — you are entitled to receive the specific criteria applied. Cross-reference those criteria against the FDA label's authorized duration, and ensure every requirement is answered with an exact chart citation.

## Practical Next Steps

1. Request the full denial letter with the specific policy number and criteria applied. 2. Ask your prescriber to draft a letter explicitly addressing the quantity requested and its alignment with the FDA label. 3. File internally within your plan's appeal deadline (noted on the denial letter). 4. If the internal appeal is denied, promptly file for independent external review — IRO reviewers are not bound by the plan's internal policies and apply accepted clinical standards.